News

Filter

Current filters:

Merck & Co

1 to 9 of 468 results

Ablynx 2014 financial results sees loss decrease thanks to collaborations

Ablynx 2014 financial results sees loss decrease thanks to collaborations

26-02-2015

Belgian drug developer Ablynx has released its 2014 full year results, reporting a decreased loss from…

AblynxBelgiumFinancialMerck & CoPharmaceutical

NICE recommends AbbVie's Humira and Merck's Remicade and Simponi for ulcerative colitis

NICE recommends AbbVie's Humira and Merck's Remicade and Simponi for ulcerative colitis

25-02-2015

The UK’s health regulator, the National Institute for Health and Care Excellence (NICE) has recommended…

AbbVieGastro-intestinalsHumiraMerck & CoPharmaceuticalRegulationRemicadeSimponi InjectionUK

Merck enters into collaboration with NGM to develop biologics

Merck enters into collaboration with NGM to develop biologics

24-02-2015

Pharma giant Merck & Co has entered into a collaboration with privately-held biotech company NGM Biopharmaceuticals…

BiotechnologyMerck & CoNGM BiopharmaceuticalsResearchUSA

Merck and Medicines Patent Pool sign licensing agreement for pediatric raltegravir

Merck and Medicines Patent Pool sign licensing agreement for pediatric raltegravir

24-02-2015

The Medicines Patent Pool has announced a license with US pharma giant Merck & Co for pediatric formulations…

Anti-viralsMerck & CoPharmaceuticalProductionRaltegravir Tablets

NewLink earns $20 million Ebola vaccine milestone from Merck

19-02-2015

US biotech firm NewLink Genetics says it had received notification from pharma giant Merck & Co that…

BiotechnologyFinancialMerck & CoNewLink GeneticsResearchTropical diseasesVaccines

Hospira’s biosimilar Inflectra comparable to Remicade in IBD treatment

Hospira’s biosimilar Inflectra comparable to Remicade in IBD treatment

19-02-2015

Positive data have been presented today on the use of Hospira's Inflectra (infliximab), the world's first…

BiosimilarsBiotechnologyGastro-intestinalsHospiraInflectraJohnson & JohnsonMerck & CoRemicadeResearch

Bristol-Myers Squibb gives full responsibility for Erbitux in Japan to Merck

Bristol-Myers Squibb gives full responsibility for Erbitux in Japan to Merck

13-02-2015

German pharmaceuticals and chemicals major Merck KGaA is to end the co-promotion of Erbitux (cetuximab)…

Bristol-Myers SquibbErbituxJapanLicensingMerck & CoOncologyPharmaceutical

1 to 9 of 468 results

COMPANY SPOTLIGHT

Menarini

Back to top